Substituted isotryptamines, or simplyisotryptamines, also known as2-(1-indolyl)ethylamines, are a group ofindoles closely related to thetryptamines but with theethylamineside chain located at the 1 position of the indolering system rather than at the 3 position as in tryptamines. Hence, they arepositional isomers of tryptamines.
^Glennon RA, Jacyno JM, Young R, McKenney JD, Nelson D (January 1984). "Synthesis and evaluation of a novel series of N,N-dimethylisotryptamines".J Med Chem.27 (1):41–45.doi:10.1021/jm00367a008.PMID6581313.
^Rasmussen K, Chytil M, Agrawal R, Leach P, Gillie D, Mungenast A, Vancutsem P, Engel S, Meyer R, Koenig A, Rus M (2024). "14. Preclinical Pharmacology of DLX-001, a Novel Non-Hallucinogenic Neuroplastogen With the Potential for Treating Neuropsychiatric Diseases".Biological Psychiatry.95 (10). Elsevier BV: S80.doi:10.1016/j.biopsych.2024.02.192.ISSN0006-3223.
^Chang-Fong J, Addo J, Dukat M, Smith C, Mitchell NA, Herrick-Davis K, Teitler M, Glennon RA (January 2002). "Evaluation of isotryptamine derivatives at 5-HT(2) serotonin receptors".Bioorg Med Chem Lett.12 (2):155–158.doi:10.1016/s0960-894x(01)00713-2.PMID11755343.
^Bishop, Michael J; Nilsson, Björn M (2003). "New 5-HT2C receptor agonists".Expert Opinion on Therapeutic Patents.13 (11):1691–1705.doi:10.1517/13543776.13.11.1691.ISSN1354-3776.
^Dutton, Alice C.; Barnes, Nicholas M. (2006). "Anti-obesity pharmacotherapy: Future perspectives utilising 5-HT2C receptor agonists".Drug Discovery Today: Therapeutic Strategies.3 (4):577–583.doi:10.1016/j.ddstr.2006.11.005.
^Nilsson BM (July 2006). "5-Hydroxytryptamine 2C (5-HT2C) receptor agonists as potential antiobesity agents".J Med Chem.49 (14):4023–4034.doi:10.1021/jm058240i.PMID16821762.
^Geldenhuys WJ, Van der Schyf CJ (2008). "Serotonin 5-HT6 receptor antagonists for the treatment of Alzheimer's disease".Curr Top Med Chem.8 (12):1035–1048.doi:10.2174/156802608785161420.PMID18691131.
^Lyon RA, Titeler M, Seggel MR, Glennon RA (January 1988). "Indolealkylamine analogs share 5-HT2 binding characteristics with phenylalkylamine hallucinogens".Eur J Pharmacol.145 (3):291–297.doi:10.1016/0014-2999(88)90432-3.PMID3350047.
^Tuck JR, Dunlap LE, Khatib YA, Hatzipantelis CJ, Weiser Novak S, Rahn RM, Davis AR, Mosswood A, Vernier AM, Fenton EM, Aarrestad IK, Tombari RJ, Carter SJ, Deane Z, Wang Y, Sheridan A, Gonzalez MA, Avanes AA, Powell NA, Chytil M, Engel S, Fettinger JC, Jenkins AR, Carlezon WA, Nord AS, Kangas BD, Rasmussen K, Liston C, Manor U, Olson DE (April 2025)."Molecular design of a therapeutic LSD analogue with reduced hallucinogenic potential".Proceedings of the National Academy of Sciences of the United States of America.122 (16) e2416106122.doi:10.1073/pnas.2416106122.PMC12037037.PMID40228113.
-5%2c6-Difluoro-isoAMT.svg)
